Honey-Derived Lactobacillus Rhamnosus Alleviates Helicobacter Pylori-Induced Gastro-Intestinal Infection and Gastric Inflammation in C57bl/6 Mice: An Immuno-Histologic Study

Abstract

BACKGROUND: Helicobacter pylori (H. pylori) has been introduced by since 1983 by Marshal and Warren to play the main role in the pathophysiology of gastritis and gastric ulcers. Almost half of the world population1 is infected by H. pylori. Current therapeutic regimen against H. pylori includes the use of a proton pump inhibitor plus two or more antibiotics. However, the efficacy of this regimen is decreasing mainly due to antibiotic resistance and side effects of medications. This fact has resulted in public interest in other therapeutic options and the role of probiotics merits special attention in this regard. OBJECTIVE: This study aims to evaluate the efficacy of honey-derived Lactobacillus rhamnosus on H. pylori-induced gastric inflammation and gastro-intestinal infection in C57BL/6 Mice. METHODS: The 24 C57BL/6 Mice were randomly divided into three groups of eight mice each. All the mice were fed with 1cc suspension containing 5*1010 CFU/ mL of ATCC43504 strains of H. pylori for 3 consecutive days, twice daily via polyethylene gavage tubes. At the end of 4th week, infection with H. pylori was confirmed with stool Ag (ELISA) and following sacrifice of one mouse from each group, histopathologic study confirmed gastritis. The groups were subjected to different therapies as stated, 1: without Bismuth (Bi), Omeprazole (Om) and L. rhamnosus prescription, 2: Bi, Om and Clarithromycin (Cl) and 3: Bi, Om plus 1cc of suspension of 109 CFU/mL of L. rhamnosus. After 2 weeks, the stool was analyzed for Ag and the mice were sacrificed for evaluation of histopathologic changes. RESULTS: Treatment with L. rhamnosus group provided Zero titer of stool Ag and was associated with improved gastric inflammation in all subjects, similar to the clarithromycin group. CONCLUSION: Honey-derived L. rhamnosus probiotics provides similar results as clarithromycin in terms of improvement of H. pylori infection and gastritis in C57BL/6 Mice model, without its cons of antibiotic resistance.

Astaxanthin n-Octanoic Acid Diester Ameliorates Insulin Resistance and Modulates Gut Microbiota in High-Fat and High-Sucrose Diet-Fed Mice

“…At the genus level, we found that Bilophila, Helicobacter, Clostridium, Dehalobacterium, and SMB53 were significantly increased after treatment with HFD. The genus Helicobacter, a potential producer of intracellular reactive oxygen species and MDA, induces gastric inflammation and gastrointestinal infection [37,38]. Moreover, an elevated abundance of Clostridium and SMB53 due to an HFD was in agreement with a previous report [39].…”

Uso De Lactobacillus Na Erradicação De Helicobacter Pylori E Na Redução De Reações Adversas Ao Tratamento Convencional: Uma Revisão Integrativa

“…H. pylori é uma bactéria patogênica móvel, que coloniza o epitélio estomacal 17 , e dois genes estão relatados aos principais fatores de virulência para induzir a patogênese, a citotoxina associada ao gene A (CagA) e a citotoxina de vacuolização A (VacA). CagA é introduzida em células hospedeiras por sistema de secreção tipo IV, a translocação de CagA nas células hospedeiras induz a ativação e produção de interleucina 8 (IL-8), quimiocina responsável pela ativação dos neutrófilos.…”

“…Na mesma direção, os autores Ji et al 16 destacaram que a cepa L. acidophilus reparou a mucosa gástrica afetada pela colonização do H. pylori. Já o estudo de Asgari et al 18 afirmou que a cepa L. rhamnosus sintetiza bacteriocinas, mas que depende da despolarização do H. pylori ocasionada pelo bismuto para que as bacteriocinas atinjam com sucesso o H. pylori, além disso, apontaram a cura da gastrite nos camundongos infectados 17 .…”

“…Nome da cepa Autores 1 Diminuição da adesão do patógeno L. fermentum García et al 15 2 Reparo da mucosa L. acidophilus Ji et al 16 3 Sintetiza bacteriocinas L. rhamnosus Asgari et al 17 Distúrbios do paladar (5 artigos)…”

“…infecção22,28. A infecção causa inflamação e dano tissular, podendo progredir para patologias graves, como ulcera péptica ou adenocarcinoma gástrico 15,17,28 . A erradicação da infecção, por H. pylori, pode reduzir amplamente o risco de lesões pré-cancerosas e câncer gástrico 16 , terapias com uso do mesmo antibiótico em altas doses, ou com uso prolongado, podem levar ao desequilíbrio da microbiota intestinal, causando e aumentando as reações adversas 25 .…”